×
About 712 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  353 results

Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating t...
https://doi.org/10.1016/j.intimp.2021.107503
International Immunopharmacology; Chen W, Su G et. al.

Mar 1st, 2021 - Our previous studies have implicated Caspase-1 signaling in driving the proinflammatory state of acute graft versus host disease (aGVHD). Therefore, we aimed to elucidate the mechanism of Caspase-1 in in murine models of aGVHD through specific inh...

An investigation of the potential association between gastrointestinal viral and bacter...
https://doi.org/10.1002/jmv.26892
Journal of Medical Virology; Bueno F, Albert E et. al.

Feb 19th, 2021 - It is uncertain whether gastrointestinal (GI) infection caused by viral and bacterial pathogens may predispose to gastrointestinal acute Graft-versus-host disease (aGvHD-GI) in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). ...

Drug delivery formulation impacts cyclosporine efficacy in a humanised mouse model of a...
https://doi.org/10.1016/j.trim.2021.101373
Transplant Immunology; Corbett JM, Hawthorne I et. al.

Feb 16th, 2021 - Acute graft versus host disease (aGvHD) is an allogeneic T cell mediated disease which manifests as a severe inflammatory disease affecting multiple organs including the liver, skin, lungs and gastrointestinal tract. Existing prophylactic and ther...

Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney t...
https://doi.org/10.1111/cts.12956
Clinical and Translational Science; Zhu J, Campagne O et. al.

Jan 27th, 2021 - Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Previous population pharmacokinetic (PK) models have been developed in soli...

see more →

Clinicaltrials.gov  357 results

Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating t...
https://doi.org/10.1016/j.intimp.2021.107503
International Immunopharmacology; Chen W, Su G et. al.

Mar 1st, 2021 - Our previous studies have implicated Caspase-1 signaling in driving the proinflammatory state of acute graft versus host disease (aGVHD). Therefore, we aimed to elucidate the mechanism of Caspase-1 in in murine models of aGVHD through specific inh...

An investigation of the potential association between gastrointestinal viral and bacter...
https://doi.org/10.1002/jmv.26892
Journal of Medical Virology; Bueno F, Albert E et. al.

Feb 19th, 2021 - It is uncertain whether gastrointestinal (GI) infection caused by viral and bacterial pathogens may predispose to gastrointestinal acute Graft-versus-host disease (aGvHD-GI) in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). ...

Drug delivery formulation impacts cyclosporine efficacy in a humanised mouse model of a...
https://doi.org/10.1016/j.trim.2021.101373
Transplant Immunology; Corbett JM, Hawthorne I et. al.

Feb 16th, 2021 - Acute graft versus host disease (aGvHD) is an allogeneic T cell mediated disease which manifests as a severe inflammatory disease affecting multiple organs including the liver, skin, lungs and gastrointestinal tract. Existing prophylactic and ther...

Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney t...
https://doi.org/10.1111/cts.12956
Clinical and Translational Science; Zhu J, Campagne O et. al.

Jan 27th, 2021 - Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Previous population pharmacokinetic (PK) models have been developed in soli...

see more →

News  2 results

Morning Break: Teva Pays for Opioid Crisis; Burnout A Real Diagnosis; 60 New Measles Cases
https://www.medpagetoday.com/primarycare/generalprimarycare/80082

May 28th, 2019 - Note that some links may require subscriptions. Teva Pharmaceuticals agreed to an $85 million settlement with Oklahoma over an alleged role in the state's opioid crisis -- which the company denied. (CNN) Incyte announced the FDA expanded indicatio...

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study
https://www.reuters.com/article/us-mesoblast-study/mesoblast-stem-cell-therapy-meets-goal-of-pediatric-graft-vs-host-study-idUSKCN1G52W2

Feb 21st, 2018 - (Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian ...

see more →